Johnson & Johnson

JNJ

Market cap $571B

Investors love dividend stocks because they provide dependable passive income streams and an excellent opportunity for solid total return.

The market's fear gauge tells the story clearly. The VIX hit 21.15 as of March 4, 2026, up 29.4% in a single month.

In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $239.63, denoting a -2.31% move from the preceding trading day.

Two Johnson & Johnson units have agreed to pay $65 million to settle a proposed antitrust class action by health plans and others claiming they were ​overcharged for the pulmonary hypertension drug Tracleer.

Approval based on unprecedented Phase 3 data demonstrating statistically significant improvements in progression – free survival and overall survival versus standard of care regimens 83.3% of patients were alive at three years, indicating durable clinical benefit HORSHAM, Pa., March 5, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced that the U.S. Food and Drug Administration (FDA) approved TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent.1 TECVAYLI® and DARZALEX FASPRO ® work synergistically to prime and activate the immune system to eradicate myeloma cells that express the BCMA protein.1 This approval offers a potential new standard of care (SOC) as early as second line and brings a novel treatment approach for the 40% of patients with multiple myeloma who experience disease relapse.2   Multimedia assets for media are available  here.

The U.S. Food and ​Drug Administration on ‌Thursday approved Johnson & Johnson's treatment ​for a ​type of blood ⁠cancer, making ​it the third ​drug cleared under the agency's new ​speedy review ​program.

Johnson & Johnson has launched a website to sell some of its drugs directly ​to U.S. patients who either don't have ‌insurance or pay for their drugs out of pocket.

Volatility is again picking up, and it's a good idea to focus more on safety.

Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Johnson & Johnson (JNJ) Presents at TD Cowen 46th Annual Health Care Conference Transcript